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ABSTRACT 
IDENTIFICATION OF INHIBITORS OF FXII 
(Under the direction of Dr. Ziaeddin Shariat-Madar) 
 
 
Hereditary angioedema is characterized by recurrent swelling of the extremities, 
larynx, and gastrointestinal tract. While type I and type II hereditary angioedema result 
from a C1-inhibitor deficiency, a new variant of the disease, type III hereditary 
angioedema, was recently discovered in individuals with functioning levels of the C1-
inhibitor. Ongoing research has postulated that increased activity of factor XII is 
responsible for this new form of hereditary angioedema because it causes overproduction 
of bradykinin. The purpose of the experiment was to identify inhibitors of factor XII. One 
hundred and seventy six molecules were screened through a dose response using Human 
Factor alpha-XIIa as the enzyme and 4nM S2302 as the substrate, while incubated in 
HEPES-carbonate buffer. The molecules were chosen from The University of Mississippi 
National Center for National Products Research after being extracted from plants 
exhibiting anti-inflammatory properties.  Seven compounds inhibited factor XII at 
concentrations ranging from 0.03 to 10nM. After multiple assays, three compounds from 
Plate NCNPR-XTL-036:Daughter showed a significant decrease in FXII activity. B7, E2, 
and H7 were identified to be inhibitors of FXII.  
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INTRODUCTION 
Blood coagulation serves a fundamental role in maintaining vascular integrity, 
specifically due to its responsibility of initiating blood clot formation. In the early 1950s, 
John Hageman was taken into observation following routine pre-operative studies 
because his blood, after being examined in glass test tubes, presented with prolonged 
clotting times.1 However, the patient revealed no history of hemorrhagic complications or 
bleeding disorders.1 Doctors, Oscar Ratnoff and Joan Colopy, noticed an active clotting 
factor was missing, which could be generated upon exposure to a glass surface, 
contributing to their theory that blood-clotting factors circulate as inactive precursors, 
which can later be activated.2 Rantoff, in collaboration with Earl Davie, discovered this 
disorder, which became known as Hageman trait or Hageman factor deficiency, was due 
to a missing plasma protein, later identified as factor XII.2  
Absence of factor XII inhibits the activation of factor XI (FXI), which becomes 
activated to factor XIa—a critical intermediate of the intrinsic pathway of blood 
coagulation.3 These revolutionary studies contributed to Rantoff and Davie’s hypothesis 
of a waterfall sequence to explain the function of various clotting factors enlisted in the 
blood coagulation system.3 A similar scheme was also proposed by Robert Macfarlane in 
the same year.3 In these models, blood coagulation advances through a chain of 
proteolytic reactions involving various enzymes that form a biochemical amplifier, 
concluding in the generation of adequate thrombin to form a blood clot.4 Fibrin formation 
can be triggered through two distinct pathways, either initiated by exposure of blood to 
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an injured vessel wall (extrinsic) or contact with circulating blood-borne factors 
(intrinsic).5  
Factor XII (FXII) circulates as an inactivated zymogen that undergoes a 
conformational change upon contact with surfaces possessing negatively charged 
properties, resulting in activated factor XII (FXIIa), which then activates FXI and 
prekallikrein (PK) in two separate pathways.6 First, in the Kallikrein-Kinin System 
(KKS), FXIIa activates PK to plasma kallikrein (KAL).6  KAL cleaves high molecular 
weight kininogen (HK), resulting in the liberation of the inflammatory mediator 
bradykinin (BK).6 The binding of BK to the kinin B2 receptor (B2R) triggers 
vasodilatation, chemotaxis of neutrophils, and increased vascular permeability.7 
Secondly, in the intrinsic pathway of coagulation, FXIIa activates factor XI (FXI) to 
activated factor XI (FXIa), which activates factor IX (FIX) to activated factor IX (FIXa), 
which activates factor X (FX) to activated factor X (FXa), which triggers fibrin 
formation.6 Thus, FXII appears to mediate multiple physiological pathways via the 
kallikrein kinin-system and intrinsic pathway, resulting in thrombosis and angioedema, as 
depicted in Figure 1.   
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Figure 1: The Intrinsic Pathway of Coagulation and the Kallikrein-Kinin System. 
Source: Donner A. The XII factor. SciBX: Science-Business eXchange. 2014 Feb 
27;7(8). 
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CHAPTER 1: HEREDITARY ANGIOEDEMA TYPE I AND II AND C1-
INHIBITOR 
 
1.1 Discovery of Hereditary Angioedema  
 In 1876, J.I. Milton first described hereditary angioedema.9 Six years later, 
Quincke assigned the name “angioneurotic edema” to the disease, adding the word 
neurotic in an effort to describe the mental stress of the manifestations of the disease.9 In 
1888, William Osler published an article characterizing a familial form of angioedema, 
despite the biochemical basis of the disease not being described for many years to 
come.10 Osler named the disease hereditary angio-neurotic edema (HANE), which has 
subsequently been shortened to simply hereditary angioedema (HAE). 10 Almost a 
century later, in 1963, Virginia Donaldson and Richard Evans first identified the 
pathophysiological basis of HAE attributing the absence of C1-inhibitor (C1-INH) in 
patients with the disease.11  
 
1.1.1 Clinical Presentation of Hereditary Angioedema 
 Hereditary angioedema (HAE) is a rare autosomal dominant disease characterized 
by recurrent angioedema attacks, involving skin swellings of the face, genitals, and 
extremities, occurring spontaneously or secondary to trauma.12, 13, 14 The angioedema 
episodes can also be accompanied by potentially life threatening laryngeal edema, with 
risk of asphyxiation, and/or severe abdominal pain due to gastrointestinal swelling.15 
Attacks may affect multiple sites of the body simultaneously or sequentially.15 Symptoms 
of HAE are generally mild to nonexistent during childhood, usually first manifesting 
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during the second decade of a patient’s life.17 However, a multitude of precipitating 
factors have been shown to induce the frequency of angioedema attacks including 
infection, emotional stress, menstruation, pregnancy, estrogen-containing agents, and 
angiotensin-converting enzyme inhibitors.16, 17  
 
1.1.2 Epidemiologic Characteristics of Hereditary Angioedema 
 While epidemiological statistics are limited, it is estimated that one in 10,000 to 
one in 150,000 individuals in the general population suffer from HAE.9 Cases of type I 
and II HAE reveal no predominance in sex, ethnicity, or race.9 However, recent evidence 
identifying a third type of HAE has been found only in women.18 Seventy-five percent of 
individuals present with cutaneous angioedema as the first indication of HAE.9 An 
estimated 45% of patients presenting in the emergency room with an HAE attack are 
subsequently hospitalized, although this is probably underestimated due to the likely 
diagnostic uncertainty of symptoms.19 Symptoms of HAE can be debilitating and 
significantly impact quality of life.20 In one study, 34% of HAE patients suffered from 
productivity impairment and 43% indicated depressive symptomatology.20 Overall, 
depending on the frequency and severity of HAE attacks, the average individual is 
incapacitated for 20-100 days out of the year.14   
 
1.1.3 Genetics of Hereditary Angioedema 
 In 1888, Osler identified the inheritance pattern of HAE as autosomal dominant.10 
Only heterozygotes have been described in the literature.10 Thus, since HAE does not 
skip generations, every child of an affected individual has a 50% chance of acquiring the 
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disease genotype.21 Phenotypically, type I HAE manifests as reduced production of C1-
INH; whereas, type II HAE results from normal levels of abnormally produced C1-INH 
proteins.9 While approximately 75% of affected patients report a family history of HAE, 
the remaining 25% of patients apparently undergo de novo mutations and/or exon 
deletions in the C1-INH gene contributing to their development of HAE.21  
 
 
1.2 Background on C1-Inhibitor  
C1 esterase inhibitor is an α2-globulin, weighing 105 kD, that is synthesized 
primarily by hepatocytes.14 The 17,159-base pair genome sequence was published in 
1991 and was later named SERPING1, located on chromosome 11 (p11.2-q13). 22 C1-
inhibitor plays a role in regulating several pathways of the body, as indicated in Figure 2. 
C1-INH regulates the complement system by inhibiting C1r, C1s, and mannose-binding 
lectin-associated serine protease 1 (MASP-1) and mannose-binding lectin-associated 
serine protease 2 (MASP-2). 23 C1-INH modulates the Kallikrein-Kinin System through 
regulation of FXII and kallikrein.23 Also, C1-INH modifies the intrinsic pathway 
coagulation by inactivating fibrinolytic proteases including FXIa and FXIIa.23 Of these 
pathways, the regulation of FXII and kallikrein, which ultimately releases bradykinin, is 
responsible for the manifestation of HAE.23 
Furthermore, it has been shown that HAE results from C1-INH deficiencies, 
which results from mutations in the SERPING1 gene.24 Classic HAE types I and II are 
associated with an insufficient C1 inhibitor (C1-INH) protein due to mutations in 
SERPING1, the gene encoding the C1 inhibitor.24 Type I HAE, accounting for 85% of 
cases, is characterized by reduced levels of C1-INH resulting from a deficiency in the 
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amount of C1-INH produced, due to SERPING1 deletions.13, 17 Type II HAE is 
characterized by normal or elevated C1-INH levels, but compromised protein function, 
due to SERPING1 missense mutations.12 Additionally, recently, a third type of HAE was 
discovered that does not present with a deficiency in C1-INH.12  
 
1.2.1 C1-Inhibitor and the Factor XII-Driven Cascade 
 C1-INH controls the FXII-driven cascade by inactivating FXIIa and PK; 
therefore, blocking BK production.15 However, since type I and II HAE patients suffer 
from C1-INH deficiencies, it leads to uncontrolled activity of FXII and PK, resulting in 
exaggerated BK formation, inducing angioedema episodes.15 In individuals with deficient 
C1-INH levels, anabolic androgens and antifibrinolytic medications are often used in the 
management of HAE symptoms, although significant adverse effects are common.25 
Recently, a new therapy was developed that injects nanofiltered C1-INH concentrate into 
individuals with subpar levels of C1-INH for the treatment of HAE.25 The C1-INH 
concentrate has been found to shorten the duration and reduce the frequency of acute 
angioedema attacks.25 Hence, C1-INH serves the role of controlling the coagulation 
cascade and production of FXII in individuals with regular C1-INH levels.15 Meanwhile, 
C1-INH can be reintroduced into individuals lacking sufficient C1-INH levels for the 
treatment and management of type I and II HAE.25 
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Figure 2: C1-Inhibitor Regulation of the Coagulation Cascade, Complement 
Cascade, and Contact Cascade.  
Adapted from (with minor modifications): Morgan BP. Hereditary angioedema—
Therapies old and new. New England Journal of Medicine. 2010 Aug 5;363(6):581-3.  
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CHAPTER 2: HEREDITARY ANGIOEDEMA TYPE III AND FACTOR XII 
 
2.1 Discovery of Type III Hereditary Angioedema  
 In 2000, a new version of HAE, type III, was discovered in individuals exhibiting 
normal C1-INH levels and function.18 Previously, in 1985, a group of scientists examined 
a sizable family with five women suffering from recurrent angioedema episodes 
accompanied with severe abdominal pain and asphyxiation.18 The striking difference was 
that each individual presented with normal C1-INH levels and function.18 In type III 
HAE, clinical manifestations include recurrent skin swelling, abdominal pain attacks, 
and/or upper-airway obstruction, no urticaria or family history of such, and normal C1-
INH plasma concentrations.18 Type III HAE is present in other family members; 
however, it has been found exclusively in females.18 Type III HAE is unable to be treated 
with C1-INH concentrate and has shown no efficacy when given corticosteroids or 
antihistamines.18 After performing genome linkage studies on multiples families, 
scientists excluded the C1-INH locus as the genetic cause of type III HAE and have 
instead suggested that the FXII gene is responsible for this phenotype.15  
 
2.2 Background on FXII 
 Factor XII, known as Hageman factor, is a 596 amino acid long glycoprotein with 
a molecular weight of 76,000 daltons.26 Factor XII is produced and secreted by the liver 
and circulates in the blood plasma as an inactive serine protease protein.26 FXII is 
encoded by the F12 gene and has been mapped to 5q33-qter in humans.27  
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2.2.1 Missense Mutations on the FXII Gene 
In 2006, further studies revealed two different missense mutations on the same 
locus, 5q33-qter gene of Hageman factor or FXII on chromosome 5 to be responsible for 
type III HAE.28 ‘Mutation 1’ substitutes a threonine with lysine (p.Thr309Lys); while 
‘Mutation 2’ substitutes a threonine with arginine (p.Thr309Arg).28 Both point mutations 
are located on exon 9.15 FXII is hypothesized as a strong candidate because both C1-INH 
and FXII act through the same pathway, ultimately resulting in the production of 
bradykinin.15 Since bradykinin (BK) is a potent inducer of vasodilation and vascular 
permeability, increased production of BK is believed to be responsible for the localized 
swelling in angioedema episodes observed in HAE.15 FXII circulates throughout the 
blood in zymogen form and is activated upon contact with negatively charged surfaces.26 
This activation has been linked to platelet activation.26 Activated FXII cleaves PK to 
KAL, which in combination with HK liberates BK, seen in Figure 3.15 The point 
mutations mentioned above are located in the proline-rich domain of FXII, which is one 
of the three regions utilized in binding FXII to negatively charged surfaces.29 This 
evidence greatly suggests that substituting a neutral threonine with a positively charged 
lysine in this region may further stimulate activation of FXII, due to the enhanced 
binding affinity for negatively charged surfaces gained through this substitution.15  
 
2.2.2 Estrogen and the FXII Gene 
 Estrogen has been found to cause various alterations in hemostasis and to elevate 
blood levels of multiple coagulants, including the blood-clotting factor FXII.30 This new 
type of HAE has been termed “estrogen-sensitive HAE” or “estrogen-related HAE” 
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because the severity of the angioedema attacks is amplified due to increased estrogen 
levels.31 FXII expression is increased through estrogens via estrogen-responsive elements 
in the promoter region of the gene, offering additional support of FXII’s involvement in 
type III HAE.15 The association of estrogen and FXII might explain why only women are 
affected in families harboring type III genotypes.30 Additionally, it may explain the 
correlation between the onset of angioedema attacks and periods of high estrogen 
levels—such as taking oral contraceptives, estrogen-replacement therapy, or while 
pregnant.31     
 
 
Figure 3: Contact Pathway Production with Bradykinin Production. 
Source: Davis 3rd AE. Biological effects of C1 inhibitor. Drug News Perspect. 2004 Sep 
1;17(7):439-46. 
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CHAPTER 3: EXPERIMENTAL DESIGN AND METHODOLOGY 
 
3.1 Background 
 It has been observed that increased activity of factor XII causes type III hereditary 
angioedema. Elevated activity of FXII ultimately contributes to the overproduction of 
bradykinin. Bradykinin induces vasodilation and increases vascular permeability, 
contributing to recurrent angioedema attacks. In type I and II HAE, individuals deficient 
in C1-INH are able to manage their angioedema by being treated with additional C1-INH. 
In type III HAE, increased activity of FXII causes HAE; hence, identification of 
inhibitors is necessary. The following experiment aims to identify potential inhibitors of 
FXII, in attempt to restore normal levels of FXII expression, reduce bradykinin 
production, and, in turn, theoretically alleviate signs and symptoms of type III HAE. 176 
different natural product molecules were tested to identify if inhibition of FXII 
expression occurred.  
 
3.2 Materials 
 Human Factor alpha-XIIa (HFXIIa) was purchased from Enzyme Research 
Laboratories. The Human Factor XIIa was activated from homogenous Human Factor 
XII using Dextran Sulfate, which was removed after activation. The concentration is 1.29 
mg/ml and the activity is 73.57 PEU/mg. S2302 was used as the substrate for hydrolysis 
by FXII activity. 4nM S2302 purchased was DiaPharma Group, Inc. HEPES-carbonate 
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buffer was added to the molecules for incubation. HEPES-carbonate buffer was made 
using 137mM NaCl, 3mM KCl, 12mM NaHCO3, 14.7mM HEPES, 5.5mM glucose, 
0.1% gelatin, 2mM CaCl2, and 1mM MgCl2, with a pH adjusted to 7.1 after filtration. 
Two 96-well plates were acquired from The University of Mississippi National Center for 
Natural Products Research. The first plate named NCNPR-XTL-036:Daughter had 20µL 
of 88 molecules. The second plate named NCNPR-XTL-047:Daughter had 10µL of 88 
molecules. 88 molecules from each plate were tested to detect possible inhibition of FXII.  
 
3.3 Methods 
3.3.1 FXII Concentrations 
FXIIa was used in increasing concentrations (0.5, 1, 2, 5, 10, 15, 20, 40, 60, 80, 
100, 200nM) to determine the Km. After calculating each the volume of FXIIa needed 
using the equation C1V1=C2V2, 8.3µL of 4nM S2302 was added to each concentration, 
bringing to final concentration to 0.3nM S2302, along with enough buffer to bring the 
total volume up to 110µL. 100µL of each concentration was pipetted into a CytoOne 96-
well plate. The plate was immediately placed in a BioTek Synergy 2 Multi-Mode 
Microplate Reader and incubated at 37°C for 1 hour in the dark to measure FXIIa 
activity. The plate was read at 405nm every 1 minute for the first 5 minutes, and then 
every 5 minutes for 60 minutes total. A triplicate of each assay was performed. The Km 
values of FXIIa were obtained using the Michaelis-Menten kinetics equation in GraphPad 
Prism software. The Km for the following data set was 7.535±1.475nM, with a Vmax of 
0.8048±0.0354µM/s. Finding the Km was vital to determine the optimal FXIIa 
concentration that would give the best signal, while using a fixed concentration of 
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substrate. Previously, an experiment was performed and determined the Km of the 
substrate S2302 to be 4nM. Therefore, each dose response used a fixed substrate 
concentration of 4nM S2303, with a final concentration of 0.3nM S2302, while varying 
the concentration of FXIIa.  
 
3.3.2 Combined Dose Response 
 Each plate of molecules obtained from The University of Mississippi National 
Center for Natural Products Research was tested next. NCNPR-XTL-047:Daughter rows 
A1-H11 molecules were tested first, then NCNPR-XTL-036:Daughter rows A1-H11 
molecules were tested second. The stock concentration of each molecule was 667nM. 
5µL of each compound was diluted with 45µL of HEPES-carbonate buffer to get a 
concentration of 66.7µM. Then, 5µL of the 66.7µM concentration was diluted again with 
45µL of HEPES-carbonate buffer, bringing the final concentration of each compound to 
6.67nM. Additionally, 3µL of 16.125µM FXIIa was combined with 497µL of HEPES-
carbonate buffer to produce 100nM concentration of FXIIa. 15µL of each compound, 
9µL of 100nM FXIIa, 8µL of 4nM S2302, and 78µL of HEPES-carbonate buffer were 
combined together in a 0.5mL vial, bringing the total volume to 110µL. After being 
evenly mixed, 100µL of each solution was pipetted into a CytoOne 96-well plate. The 
plate was immediately placed in a BioTek Synergy 2 Multi-Mode Microplate Reader and 
incubated at 37°C for 1 hour in the dark to measure FXIIa activity, which ultimately 
measured the percent inhibition of each molecule. The plate was read at 405nm every 15 
minutes for a total of 60 minutes.  
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3.3.3 Individual Dose Response 
 After comparing the percent inhibition by each molecule, the compounds with the 
greatest inhibition activity were highlighted. After identifying this, a dose response was 
performed on each molecule. In the dose response, one compound was tested at a time 
using increasing concentrations (0, 0.1, 0.3, 1, 3, 10nM). To get the appropriate 
concentration of FXIIa, 3.7µL of FXIIa was combined with 56.3µL of HEPES buffer to 
form 100nM FXIIa.  
After calculating the volume of each compound needed using the equation 
C1V1=C2V2, 3.3µL of 100nM FXIIa, 25µL of 4nM S2302, along with enough HEPES 
buffer to bring the total volume up to 330µL was added to each vial of increasing 
concentration. 100µL of each concentration was pipetted into a CytoOne 96-well plate. 
Triplicates of each assay were performed. The plate was immediately placed into a 
BioTek Synergy 2 Multi-Mode Microplate Reader and incubated at 37°C for 1 hour in 
the dark to measure FXIIa activity. The plate was read at 405nm every 15 minutes for 60 
minutes total. Values were measured and recorded after 60 minutes. This dose response 
was performed on molecules A3, G3, and G4 from NCNPR-XTL-047:Daughter and on 
molecules B7, E2, E3, and H7 from NCNPR-XTL-036:Daughter.  
 
3.4 Results  
 In order to determine proper timing of the dose responses, the first experiment 
measured the kinetics of S2302 cleavage by different concentrations of FXII in a time-
dependent manner. The 96-well plate was placed into a BioTek Synergy 2 Multi-Mode 
Microplate Reader at 405nm and absorbance was measured. Readings were taken at 0, 1, 
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2, 3, 5, 10, 15, 20, 25, 30, 40, 50, and 60 minutes and the activity of 10nM FXIIa was 
determined (Table 1). Following the time course, increasing concentrations of FXIIa (0, 
0.5, 1, 2, 5, 10, 15, 20, 40, 60, 80, 100, 200nM) were measured after being incubated at 
37°C for 1 hour and the activity of FXII is reported in Table 2 and Figure 4. The Km for 
the data set was 7.535±1.475nM, with a Vmax of 0.8048±0.0354µM/s. 
 The following dose responses on individual compounds were performed in the 
same manner as the time-dependent and concentration-dependent FXIIa readings. The 
96-well plate was placed into a BioTek Synergy 2 Multi-Mode Microplate Reader at 
405nm and absorbance was measured. The measurements of absorbance translate into 
FXII activity, which allows us to detect any inhibition or increase in FXII activity. 
Compounds of Plate 047 were the first to be tested with FXII to identify any decreases in 
activity, and ultimately, inhibition of FXII. As highlighted in Table 3a and Table 3b, 
compounds A3, G2, and G3 demonstrated the largest inhibition of FXII activity. The first 
dose response performed on A3 revealed decreasing activity of FXII, as the concentration 
of A3 increased, reported in Table 4a and Figure 5a. The second dose response was 
performed two weeks later, results revealed no inhibition and instead an increase in 
activity of FXII. We concluded that due to the volatility and instability of these 
compounds, waiting an additional two weeks to perform another dose response led to 
inaccurate readings for the A3 compound, exhibited in Table 4b and Figure 5b. A dose 
response was also performed on compounds G3 and G4. Both compounds revealed no 
inhibition and instead showed increasing activity of FXII. The effect of G3 on FXII 
activity is reported in Table 5 and Figure 6. The effect of G4 on FXII activity is reported 
in Table 6 and Figure 7. This ended any further testing of molecules G3 and G4.  
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 After completing the dose responses on Plate 047, Plate 036 was tested next to 
continue searching for inhibitors of FXII. As highlighted in Table 7a and Table 7b, 
compounds E2, E3, B7, and H7 revealed the greatest decrease in FXII activity. Two 
doses responses were performed on compound E2. In accordance with the initial reading, 
E2 revealed decreased activity in FXII, ranging from 49-64% inhibition shown in Table 
8a, Table 8b, and Figure 8. The dose response on E3 was performed next. However, there 
was no significant decrease in the activity of FXII, seen in Table 9 and Figure 9. Lastly, 
molecules B7 and H7 were to be tested. Due to a limiting amount of material and time, 
both molecules were only tested at one concentration of 1nM. At higher concentrations, 
compounds have the ability to become non-specific. Therefore, although only one 
concentration was used, molecule B7 revealed 35% inhibition, exhibited in Table 10, and 
H7 revealed 43% inhibition, exhibited in Table 11. These findings prove to be significant 
because such high inhibition was shown at a low concentration.  
 
3.5 Data 
 (See following pages) 
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Table 1: 10nM FXII Time Course. Readings were taken using a MicroPlate reader at 
405nm 13 times over the course of an hour to measure the activity of 10nM of FXII 
incubated with 4nM S2302 and HEPES-buffer at 37°C. This determined that further dose 
responses would be measured at 60 minutes.  
Condition: 10 O.D. Average   -Blk 
Concentration: nM   O.D.   
Time: min       
0.000 0.071     
  0.071     
  0.069 0.070 0.000 
1 0.085     
  0.085     
  0.082 0.084 0.014 
2 0.1     
  0.1     
  0.096 0.099 0.028 
3 0.105     
  0.105     
  0.101 0.104 0.033 
5 0.108     
  0.108     
  0.103 0.106 0.036 
10 0.127     
  0.128     
  0.123 0.126 0.056 
15 0.168     
  0.17     
  0.162 0.167 0.096 
20 0.191     
  0.193     
  0.183 0.189 0.119 
25 0.212     
  0.215     
  0.204 0.210 0.140 
30 0.23     
  0.237     
  0.225 0.231 0.160 
40 0.273     
  0.278     
  0.263 0.271 0.201 
50 0.31     
  0.316     
  0.299 0.308 0.238 
60 0.345     
  0.352     
  0.334 0.344 0.273 
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Table 2: FXIIa Dose Response and Km. Increasing concentrations of FXII were used to 
determine the Km and vmax. FXII was incubated with 4nM S2302 and HEPES-carbonate 
buffer for 1 hour at 37°C and a MicroPlate reader was used to measure activity at 405nm. 
The Km is the Michaelis-Menten constant, which determines the concentration of the 
substrate when the velocity of the reaction is one half of the maximal velocity.  
Condition: FXIIa O.D. Average -Blk 
Concentration: nM 
 
O.D. 
 Time: 60 min 
   0.000 0.049 
  
 
0.049 
  
 
0.05 0.049 0.000 
0.5 0.053 
  
 
0.052 
  
 
0.052 0.052 0.003 
1 0.056 
  
 
0.048 
  
 
0.058 0.054 0.005 
2 0.053 
  
 
0.059 
  
 
0.057 0.056 0.007 
5 0.311 
  
 
0.292 
  
 
0.277 0.293 0.244 
10 0.430 
  
 
0.517 
  
 
0.508 0.485 0.436 
15 0.508 
  
 
0.598 
  
 
0.567 0.558 0.508 
20 0.675 
  
 
0.683 
  
 
0.694 0.684 0.635 
40 0.691 
  
 
0.716 
  
 
0.662 0.690 0.640 
60 0.637 
  
 
0.749 
  
 
0.741 0.709 0.660 
80 0.727 
  
 
0.76 
  
 
0.751 0.746 0.697 
100 0.738 
  
 
0.74 
  
 
0.673 0.717 0.668 
200 0.731 
  
 
0.725 
  
 
0.720 0.725 0.676 
    
  
Std. 
Error 
 Km (nM) 7.535 1.475 
 Vmax (µM/s) 0.8048 0.03535 
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Figure 4: FXIIa Dose Response. Graphic form of data presented in Table 2. The graph 
was generated using GraphPad Prism software. 
 
  
!
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Table 3a: Plate NCNPR-XTL-047:Daughter %Inhibition A1-D11—The readings of 
44 out of 88 molecules from Plate 047 tested to detect FXII activity. Additional dose 
responses were performed on highlighted numbers. 
Condition: Plate 047 O.D. Average  -Blk % 
Concentration: 1nM   O.D. 
 
Activity 
Time: 60 min      
 Blk 0.05 0.052 
 
0.00 
0 0.293 0.283 0.231 100.000 
A1 0.426 0.426 0.374 161.994 
A2 0.375 0.375 0.323 139.884 
A3 0.054 0.054 0.002 0.723 
A4 0.576 0.576 0.524 227.023 
A5 0.357 0.357 0.305 132.081 
A6 0.702 0.702 0.650 281.647 
A7 0.419 0.419 0.367 158.960 
A8 0.717 0.717 0.665 288.150 
A9 0.469 0.469 0.417 180.636 
A10 0.520 0.520 0.468 202.746 
A11 0.608 0.608 0.556 240.896 
B1 0.414 0.414 0.362 156.792 
B2 0.429 0.429 0.377 163.295 
B3 0.345 0.345 0.293 126.879 
B4 0.432 0.432 0.380 164.595 
B5 0.372 0.372 0.320 138.584 
B6 0.517 0.517 0.465 201.445 
B7 0.491 0.491 0.439 190.173 
B8 0.544 0.544 0.492 213.150 
B9 0.348 0.348 0.296 128.179 
B10 0.477 0.477 0.425 184.104 
B11 0.446 0.446 0.394 170.665 
C1 0.333 0.333 0.281 121.676 
C2 0.273 0.273 0.221 95.665 
C3 0.345 0.345 0.293 126.879 
C4 0.36 0.360 0.308 133.382 
C5 0.297 0.297 0.245 106.069 
C6 0.504 0.504 0.452 195.809 
C7 0.816 0.816 0.764 331.069 
C8 0.667 0.667 0.615 266.474 
C9 0.346 0.346 0.294 127.312 
C10 0.481 0.481 0.429 185.838 
C11 0.39 0.390 0.338 146.387 
D1 0.36 0.360 0.308 133.382 
D2 0.453 0.453 0.401 173.699 
D3 0.3 0.300 0.248 107.370 
D4 0.339 0.339 0.287 124.277 
D5 0.291 0.291 0.239 103.468 
D6 0.403 0.403 0.351 152.023 
D7 0.403 0.403 0.351 152.023 
D8 0.505 0.505 0.453 196.243 
D9 0.351 0.351 0.299 129.480 
D10 0.405 0.405 0.353 152.890 
D11 0.368 0.368 0.316 136.850 
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Table 3b: Plate NCNPR-XTL-047:Daughter %Inhibition E1-H11—The readings of 
44 out of 88 molecules from Plate 047 tested to detect FXII activity. Additional dose 
responses were performed on highlighted numbers. 
Condition: Plate 047 O.D. Average  -Blk % 
Concentration: 1nM   O.D. 
 
Activity 
Time: 60 min      
 Blk 0.05 0.052 
 
0.00
0 0.293 0.283 0.231 100.000 
E1 0.303 0.303 0.251 108.671 
E2 0.327 0.327 0.275 119.075 
E3 0.216 0.216 0.164 70.954 
E4 0.24 0.240 0.188 81.358 
E5 0.273 0.273 0.221 95.665 
E6 0.428 0.428 0.376 162.861 
E7 0.4 0.400 0.348 150.723 
E8 0.435 0.435 0.383 165.896 
E9 0.581 0.581 0.529 229.191 
E10 0.411 0.411 0.359 155.491 
E11 0.612 0.612 0.560 242.630 
F1 0.288 0.288 0.236 102.168 
F2 0.255 0.255 0.203 87.861 
F3 0.282 0.282 0.230 99.566 
F4 0.255 0.255 0.203 87.861 
F5 0.225 0.225 0.173 74.855 
F6 0.615 0.615 0.563 243.931 
F7 0.546 0.546 0.494 214.162 
F8 0.43 0.430 0.378 163.728 
F9 0.404 0.404 0.352 152.457 
F10 0.273 0.273 0.221 95.665 
F11 0.337 0.337 0.285 123.410 
G1 0.3 0.300 0.248 107.370 
G2 0.255 0.255 0.203 87.861 
G3 0.21 0.210 0.158 68.353 
G4 0.222 0.222 0.170 73.555 
G5 0.258 0.258 0.206 89.162 
G6 0.475 0.475 0.423 183.237 
G7 0.655 0.655 0.603 261.272 
G8 0.402 0.402 0.350 151.590 
G9 0.252 0.252 0.200 86.561 
G10 0.277 0.277 0.225 97.399 
G11 0.359 0.374 0.321 139.306 
H1 0.246 0.246 0.194 83.960 
H2 0.318 0.318 0.266 115.173 
H3 0.276 0.276 0.224 96.965 
H4 0.423 0.423 0.371 160.694 
H5 0.258 0.258 0.206 89.162 
H6 0.559 0.559 0.507 219.653 
H7 0.27 0.270 0.218 94.364 
H8 0.461 0.461 0.409 177.168 
H9 0.378 0.378 0.326 141.185 
H10 0.375 0.375 0.323 139.884 
H11 0.326 0.326 0.274 118.642 
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Condition: A3 O.D. Average  -Blk % 
Concentration: nM   O.D.   Activity 
Time: 60 min       
 Blk 0.054       
  0.053       
  0.05 0.052     
0.000 0.654       
  0.699       
  0.695 0.683 0.630 100.000 
0.03 0.548       
  0.58       
  0.583 0.570 0.518 82.179 
0.1 0.381       
  0.38       
  0.359 0.373 0.321 50.925 
0.3 0.404       
  0.398       
  0.416 0.406 0.354 56.108 
1 0.342       
  0.353       
  0.331 0.342 0.290 45.955 
3 0.195       
  0.173       
  0.181 0.183 0.131 20.730 
 
Table 4a: Plate 047—A3 Dose Response (1)—Increasing concentrations of A3 were 
combined with 1µM FXIIa, 4nM S2302, and HEPES-carbonate buffer to detect FXII 
activity. Triplicates of each concentration were performed. The activity of FXII is 
reported. 
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Table 4b: Plate 047—A3 Dose Response (2)— Increasing concentrations of A3 were 
combined with 1µM FXIIa, 4nM S2302, and HEPES-carbonate buffer to detect FXII 
activity. Experiment was performed two weeks after the first testing of A3. Triplicates of 
each concentration were performed. No inhibition was shown. 
 
 
  
Condition: A3 O.D. Average  -Blk % 
Concentration: nM   O.D.   Activity 
Time: 60 min         
Blk 0.054       
  0.053       
  0.05 0.052     
0.000 0.396       
  0.442       
  0.458 0.432 0.380 100.000 
0.01 0.521       
  0.558       
  0.582 0.554 0.501 132.046 
0.03 0.512       
  0.578       
  0.576 0.555 0.503 132.485 
0.1 0.709       
  0.811       
  0.823 0.781 0.729 191.923 
0.3 0.462       
  0.493       
  0.531 0.495 0.443 116.681 
1 0.813       
  0.831       
  0.826 0.823 0.771 203.073 
3 0.645       
  0.665       
  0.685 0.665 0.613 161.370 
10 0.820       
  0.836       
  0.875 0.844 0.791 208.428 
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Figure 5a: Plate 047—A3 Dose Response (1)— Graphic form of data presented in 
Table 5a. The graph was generated using GraphPad Prism software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5b: Plate 047—A3 Dose Response (2)—Graphic form of data presented in Table 
5b. The graph was generated using GraphPad Prism software. 
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Table 5: Plate 047—G3 Dose Response—Increasing concentrations of G3 were 
combined with 1µM FXIIa, 4nM S2302, and HEPES-carbonate buffer to detect FXII 
activity. Triplicates of each concentration were performed. No inhibition was shown. 
 
  
Condition: G3 O.D. Average  -Blk % 
Concentration: nM   O.D.   Activity 
Time: 60 min         
Blk 0.054       
  0.053       
  0.05 0.052     
0.000 0.372       
  0.37       
  0.37 0.371 0.318 100.000 
0.01 0.525       
  0.525       
  0.525 0.525 0.473 148.482 
0.03 0.322       
  0.358       
  0.375 0.352 0.299 94.031 
0.1 1.197       
  1.215       
  1.192 1.201 1.149 360.942 
0.3 1.042       
  0.1087       
  1.101 0.751 0.698 219.340 
1 1.015       
  1.02       
  1.035 1.023 0.971 305.026 
3 0.611       
  0.666       
  0.687 0.655 0.602 189.215 
10 1.200       
  1.204       
  1.307 1.237 1.185 372.147 
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Condition: G4 O.D. Average  -Blk % 
Concentration: nM   O.D.   Activity 
Time: 60 min         
Blk 0.054       
  0.053       
  0.05 0.052     
0.000 0.519       
  0.543       
  0.508 0.523 0.471 147.958 
0.01 0.348       
  0.35       
  0.327 0.342 0.289 90.890 
0.03 0.322       
  0.322       
  0.322 0.322 0.270 84.712 
0.1 0.3       
  0.308       
  0.321 0.310 0.257 80.838 
0.3 0.353       
  0.376       
  0.373 0.367 0.315 98.953 
1 0.363       
  0.375       
  0.367 0.368 0.316 99.267 
3 0.36       
  0.414       
  0.389 0.388 0.335 105.340 
10 0.742       
  0.733       
  0.799 0.758 0.706 221.675 
 
Table 6: Plate 047—G4 Dose Response— Increasing concentrations of G4 were 
combined with 1µM FXIIa, 4nM S2302, and HEPES-carbonate buffer to detect FXII 
activity. Triplicates of each concentration were performed. No inhibition was shown. 
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Figure 6: Plate 047—G3 Dose Response— Graphic form of data presented in Table 6. 
The graph was generated using GraphPad Prism software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Plate 047—G4 Dose Response— Graphic form of data presented in Table 7. 
The graph was generated using GraphPad Prism software. 
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Table 7a: Plate NCNPR-XTL-036:Daughter %Inhibition A1-D11—The readings of 
44 out of 88 molecules from Plate 036 tested to detect FXII activity. Additional dose 
responses were performed on highlighted numbers. 
  
Condition: Plate 036 O.D. Average  -Blk % 
Concentration: 1nM   O.D.   Activity 
Time: 60 min       
 Blk 0.054 0.052     
0 0.432 0.432 0.380 100.000 
A1 0.264 0.275 0.455 204.192 
A2 0.507 0.507 0.458 205.539 
A3 0.51 0.51 0.330 148.054 
A4 0.38 0.382 0.311 139.521 
A5 0.332 0.332 0.280 125.599 
A6 0.314 0.314 0.262 117.515 
A7 0.822 0.822 0.770 202.544 
A8 0.558 0.558 0.506 133.070 
A9 0.834 0.834 0.782 205.702 
A10 0.884 0.884 0.832 218.860 
A11 0.752 0.752 0.700 184.123 
B1 0.192 0.192 0.140 62.725 
B2 0.435 0.435 0.383 171.856 
B3 0.435 0.435 0.383 171.856 
B4 0.310 0.310 0.258 115.719 
B5 0.643 0.643 0.591 265.269 
B6 0.504 0.504 0.452 202.844 
B7 0.139 0.139 0.087 22.807 
B8 0.566 0.566 0.514 135.175 
B9 0.501 0.501 0.449 118.070 
B10 0.582 0.582 0.530 139.386 
B11 0.558 0.558 0.506 133.070 
C1 0.336 0.336 0.284 127.395 
C2 0.263 0.263 0.211 94.611 
C3 0.301 0.301 0.249 111.677 
C4 0.306 0.306 0.254 113.922 
C5 0.469 0.469 0.417 187.126 
C6 0.331 0.331 0.279 125.150 
C7 0.706 0.706 0.654 172.018 
C8 0.609 0.609 0.557 146.491 
C9 0.367 0.367 0.315 82.807 
C10 0.432 0.432 0.380 99.912 
C11 0.423 0.423 0.371 97.544 
D1 0.312 0.312 0.260 116.617 
D2 0.421 0.421 0.369 165.569 
D3 0.258 0.258 0.206 92.365 
D4 0.388 0.388 0.336 150.749 
D5 0.206 0.206 0.154 69.012 
D6 0.202 0.202 0.150 67.216 
D7 0.392 0.392 0.340 89.386 
D8 0.479 0.479 0.427 112.281 
D9 0.367 0.367 0.315 82.807 
D10 0.347 0.347 0.295 77.544 
D11 0.441 0.441 0.389 102.281 
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Table 7b: Plate NCNPR-XTL-036:Daughter %Inhibition E1-H11—The readings of 
44 out of 88 molecules from Plate 036 tested to detect FXII activity. Additional dose 
responses were performed on highlighted numbers. 
  
Condition: Plate 036 O.D. Average  -Blk % 
Concentration: 1nM   O.D.   Activity 
Time: 60 min       
 Blk 0.054 0.052     
0 0.275 0.275 0.223 100.000 
E1 0.693 0.693 0.641 287.725 
E2 0.045 0.045 -0.007 -3.293 
E3 0.063 0.063 0.011 4.790 
E4 0.656 0.656 0.604 271.108 
E5 0.582 0.582 0.530 237.874 
E6 0.394 0.394 0.342 153.443 
E7 0.409 0.409 0.357 93.860 
E8 0.337 0.337 0.285 74.912 
E9 0.332 0.332 0.280 73.596 
E10 0.295 0.295 0.243 63.860 
E11 0.313 0.313 0.261 68.596 
F1 0.429 0.429 0.377 169.162 
F2 0.258 0.258 0.206 92.365 
F3 0.374 0.374 0.322 144.461 
F4 0.275 0.275 0.223 100.000 
F5 0.248 0.248 0.196 87.874 
F6 0.263 0.263 0.211 94.611 
F7 0.397 0.397 0.345 90.702 
F8 0.363 0.363 0.311 81.754 
F9 0.378 0.378 0.326 85.702 
F10 0.303 0.303 0.251 65.965 
F11 0.590 0.590 0.538 141.491 
G1 0.247 0.247 0.195 87.425 
G2 0.275 0.275 0.223 100.000 
G3 0.419 0.419 0.367 164.671 
G4 0.452 0.452 0.400 179.491 
G5 0.433 0.433 0.381 170.958 
G6 0.335 0.335 0.283 126.946 
G7 0.649 0.649 0.597 157.018 
G8 0.919 0.919 0.867 228.070 
G9 0.634 0.634 0.582 153.070 
G10 0.521 0.521 0.469 123.333 
G11 0.525 0.525 0.473 124.386 
H1 0.447 0.447 0.395 177.246 
H2 0.537 0.537 0.485 217.665 
H3 0.327 0.327 0.275 123.353 
H4 0.384 0.384 0.332 148.952 
H5 0.337 0.337 0.285 127.844 
H6 0.33 0.330 0.278 124.701 
H7 0.076 0.076 0.024 6.228 
H8 0.396 0.396 0.344 90.439 
H9 0.771 0.771 0.719 189.123 
H10 0.425 0.425 0.373 98.070 
H11 0.257 0.257 0.205 53.860 
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Condition: E2 O.D. Average  -Blk % 
Concentration: nM   O.D.   Activity 
Time: 60 min       
 Blk 0.054       
  0.053       
  0.05 0.052     
0.000 0.464       
  0.484       
  0.483 0.477 0.425 100.000 
0.03 0.743       
  0.721       
  0.583 0.682 0.630 148.352 
0.1 0.65       
  0.588       
  0.595 0.611 0.559 131.554 
0.3 0.381       
  0.375       
  0.367 0.374 0.322 75.824 
1 0.306       
  0.319       
  0.307 0.311 0.258 60.832 
3 0.279       
  0.29       
  0.295 0.288 0.236 55.495 
10 0.249       
  0.264       
  0.269 0.261 0.208 49.058 
 
Table 8a: Plate 036—E2 Dose Response (1)—Increasing concentrations of E2 were 
combined with 1µM FXIIa, 4nM S2302, and HEPES-carbonate buffer to detect FXII 
activity. Triplicates of each concentration were performed.  
 
 
 
  
32 
Condition: E2 O.D. Average  -Blk % 
Concentration: nM   O.D.   Activity 
Time: 60 min         
Blk 0.054       
  0.053       
  0.05 0.052     
0.000 0.604       
  0.645       
  0.647 0.632 0.580 100.000 
0.03 0.668       
  0.757       
  0.832 0.752 0.700 120.759 
0.1 0.56       
  0.634       
  0.626 0.607 0.554 95.630 
0.3 0.52       
  0.56       
  0.62 0.567 0.514 88.729 
1 0.387       
  0.505       
  0.481 0.458 0.405 69.925 
3 0.376       
  0.442       
  0.453 0.424 0.371 64.060 
 
Table 8b: Plate 036—E2 Dose Response (2)—Increasing concentrations of E2 were 
combined with 1µM FXIIa, 4nM S2302, and HEPES-carbonate buffer to detect FXII 
activity. Triplicates of each concentration were performed. The activity of FXII is 
reported. 
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Figure 8: Plate 036—Combined E2 Dose Response— Graphic form of the combined 
data presented in Table 8a and 8b. The graph was generated using GraphPad Prism 
software. 
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Condition: E3 O.D. Average  -Blk % 
Concentration: nM   O.D.   Activity 
Time: 60 min         
Blk 0.054       
  0.053       
  0.05 0.052     
0.000 0.414       
  0.451       
  0.438 0.434 0.382 100.000 
0.03 0.467       
  0.524       
  0.525 0.505 0.453 118.586 
0.1 0.429       
  0.46       
  0.471 0.453 0.401 104.974 
0.3 0.409       
  0.433       
  0.414 0.419 0.366 95.899 
1 0.397       
  0.407       
  0.435 0.413 0.361 94.415 
3 0.413       
  0.446       
  0.352 0.404 0.351 91.972 
 
Table 9: Plate 036—E3 Dose Response— Increasing concentrations of E3 were 
combined with 1µM FXIIa, 4nM S2302, and HEPES-carbonate buffer to detect FXII 
activity. Triplicates of each concentration were performed. No inhibition was shown.  
 
  
35 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Plate 036—E3 Dose Response—Graphic form of the combined data presented 
in Table 9. The graph was generated using GraphPad Prism software. 
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Condition: B7 O.D. Average  -Blk % 
Concentration: nM   O.D.   Activity 
Time: 60 min       
 Blk 0.054       
  0.053       
  0.05 0.052     
0.000 0.365       
  0.355       
  0.332 0.351 0.298 100.000 
1 0.26       
  0.233       
  0.248 0.247 0.195 65.251 
 
Table 10: Plate 036—B7 Dose Response— One concentration of B7 was combined 
with 1µM FXIIa, 4nM S2302, and HEPES-carbonate buffer to detect FXII activity. 
Triplicates were performed. 
 
 
 
 
 
 
 
Condition: H7 O.D. Average  -Blk % 
Concentration: nM   O.D.   Activity 
Time: 60 min       
 Blk 0.054       
  0.053       
  0.05 0.052     
0.000 0.365       
  0.355       
  0.332 0.351 0.298 100.000 
1 0.216       
  0.239       
  0.216 0.224 0.171 57.430 
 
Table 11: Plate 036—H7 Dose Response— One concentration of H7 was combined 
with 1µM FXIIa, 4nM S2302, and HEPES-carbonate buffer to detect FXII activity. 
Triplicates were performed. 
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CHAPTER 4: DISCUSSION 
 Factor XII plays a pivotal role in the regulation and activation of blood 
coagulation and the contact cascade system. Recently, a new variant of hereditary 
angioedema, type III, was discovered in individuals with normal C1-INH levels. Upon 
further examination of these individuals with type III HAE, it has been hypothesized that 
point mutations in FXII are responsible for the manifestation of the disease phenotype. 
The consequence of the mutation is increased activity of FXII, which, in turn, causes the 
overproduction of bradykinin. Bradykinin causes increased vascular permeability and 
vasodilation as seen in HAE patients. Since increased activity in FXII has been noted to 
cause type III HAE, we wanted to identify inhibitors that could potentially decrease FXII 
activity and restore it to regular functioning levels. The implication of an inhibitor serves 
as a potential treatment target to alleviate the symptoms and frequency of reoccurring 
angioedema attacks in patients.  
The purpose of this experiment was to identify inhibitors of FXII. Three samples, 
B7, E2, and H7 of Plate NCNPR-XTL-036:Daughter, demonstrated a significant decrease 
in FXII activity, reducing FXII’s activity from 49-65% its original values. B7 exhibited 
35% inhibition; E2 exhibited 36-51% inhibition; and H7 exhibited 43% inhibition. These 
three compounds are identified as inhibitors of FXII. The experiment does have a few 
limitations. Since the concentrations used for each dose response were not consistent, 
more experiments must be performed in order to prove validity. Additionally, it can be 
noted that due to the volatility of the compounds, they might have lost their original 
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activity after a few weeks. This could be due to the fact that the compounds were not 
directly extracted from the plant compounds for the experiment. In conclusion, the data 
presented identified three compounds exhibiting inhibition of FXII. These findings have 
the ability to impact future treatments of those suffering with type III HAE. Further 
studies are necessary to prove validity, to identify how the molecule is inhibiting FXII, 
and to identify if the molecule has the ability to decrease bradykinin production. After 
these findings are validated, future studies include if and how this molecule could be 
incorporated into a treatment regimen for the symptomatic relief of patients with type III 
hereditary angioedema.   
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